Last reviewed · How we verify
R-mini-CHOP
R-mini-CHOP is a chemotherapy regimen that combines rituximab with a modified version of the CHOP regimen, which includes cyclophosphamide, doxorubicin, vincristine, and prednisone.
R-mini-CHOP is a chemotherapy regimen that combines rituximab with a modified version of the CHOP regimen, which includes cyclophosphamide, doxorubicin, vincristine, and prednisone. Used for Follicular lymphoma, Diffuse large B-cell lymphoma.
At a glance
| Generic name | R-mini-CHOP |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Chemotherapy regimen |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
R-mini-CHOP is used to treat certain types of non-Hodgkin lymphoma. The addition of rituximab to the CHOP regimen has been shown to improve outcomes in patients with these diseases. The exact mechanism of action of rituximab is not fully understood, but it is thought to work by binding to CD20 on the surface of B cells and marking them for destruction.
Approved indications
- Follicular lymphoma
- Diffuse large B-cell lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Infection
- Fatigue
Key clinical trials
- Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL (PHASE2)
- AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL (PHASE3)
- Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (PHASE1, PHASE2)
- A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL
- A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) (PHASE2)
- A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma (PHASE3)
- Dose Dense Chemotherapy in Elderly Patients > 80 Years Old With DLBCL
- Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |